Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Sees Significant Drop in Short Interest

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a large decrease in short interest in February. As of February 27th, there was short interest totaling 45,206 shares, a decrease of 38.2% from the February 12th total of 73,194 shares. Currently, 3.2% of the company’s stock are sold short. Based on an average daily volume of 58,738 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily volume of 58,738 shares, the days-to-cover ratio is currently 0.8 days. Currently, 3.2% of the company’s stock are sold short.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals during the 4th quarter valued at about $26,000. Boothbay Fund Management LLC bought a new position in Shuttle Pharmaceuticals in the fourth quarter worth about $37,000. Ikarian Capital LLC acquired a new position in Shuttle Pharmaceuticals in the fourth quarter valued at approximately $124,000. Finally, Connective Capital Management LLC acquired a new position in Shuttle Pharmaceuticals in the third quarter valued at approximately $357,000. 4.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Trading Up 1.5%

Shuttle Pharmaceuticals stock traded up $0.01 during mid-day trading on Friday, reaching $0.94. The company’s stock had a trading volume of 38,025 shares, compared to its average volume of 82,259. Shuttle Pharmaceuticals has a twelve month low of $0.80 and a twelve month high of $13.75. The business has a 50 day moving average price of $1.46 and a 200-day moving average price of $2.36. The firm has a market cap of $1.50 million, a price-to-earnings ratio of -0.08 and a beta of -0.82.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .